File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Remifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats

TitleRemifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of rats
Authors
KeywordsChelerythrine
GF109203X
Myocardial ischemia preconditioning
Myocardial reperfusion injury
Protein kinase C
Remifentanil
Issue Date2005
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/aps/index.html
Citation
Acta Pharmacologica Sinica, 2005, v. 26 n. 5, p. 546-550 How to Cite?
AbstractAim: To examine whether the protective effect of remifentanil preconditioning (RPC) on postischemic hearts is mediated by protein kinase (PKC) activation in comparison with ischemic preconditioning (IPC). Methods: Male Sprague-Dawley rats were anesthetized and their chests were opened. The experiment was performed with chelerythrine (CHE, 2 mg/kg), GF109203X (0.05 mg/kg) protein kinase C (PKC) inhibitors administered before RPC (remifentanil 6 μg·kg-1·min-1×3 cycle) or IPC, respectively. Infarct size (IS), as a percentage of the area at risk (AAR), was determined by triphenyltetrazolium staining. Results: In groups subjected to IPC and RPC the IS/AAR were significantly reduced (IS/AAR from 52.7%±5.5% to 12.9%±3.4%, P<0.01 vs CON and 16.2%±6.4%, P<0.01 vs CON), respectively. CHE and GF, both PKC inhibitors, administered 5 min before RPC or IPC completely abolished the cardioprotective effect of RPC (IS/AAR: CHE+RPC 51.2%±5.0%, GF+RPC 53.6%±6.1%, P>0.05 vs CON) or IPC (CHE+IPC 53.7%±4.3%, GF+IPC 54.1%±6.2%, P>0.05 vs CON). The difference was not significant in any of the hemodynamic parameters between control and treatment groups during ischemia and reperfusion. Conclusion: Remifentanil confers myocardial protection against ischemic injury through a mechanism that is similar to IPC and involves PKC activation. ©2005 CPS and SIMM.
Persistent Identifierhttp://hdl.handle.net/10722/145541
ISSN
2015 Impact Factor: 3.166
2015 SCImago Journal Rankings: 1.161
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorZhang, Yen_HK
dc.contributor.authorChen, ZWen_HK
dc.contributor.authorIrwin, MGen_HK
dc.contributor.authorWong, TMen_HK
dc.date.accessioned2012-02-28T01:53:18Z-
dc.date.available2012-02-28T01:53:18Z-
dc.date.issued2005en_HK
dc.identifier.citationActa Pharmacologica Sinica, 2005, v. 26 n. 5, p. 546-550en_HK
dc.identifier.issn1671-4083en_HK
dc.identifier.urihttp://hdl.handle.net/10722/145541-
dc.description.abstractAim: To examine whether the protective effect of remifentanil preconditioning (RPC) on postischemic hearts is mediated by protein kinase (PKC) activation in comparison with ischemic preconditioning (IPC). Methods: Male Sprague-Dawley rats were anesthetized and their chests were opened. The experiment was performed with chelerythrine (CHE, 2 mg/kg), GF109203X (0.05 mg/kg) protein kinase C (PKC) inhibitors administered before RPC (remifentanil 6 μg·kg-1·min-1×3 cycle) or IPC, respectively. Infarct size (IS), as a percentage of the area at risk (AAR), was determined by triphenyltetrazolium staining. Results: In groups subjected to IPC and RPC the IS/AAR were significantly reduced (IS/AAR from 52.7%±5.5% to 12.9%±3.4%, P<0.01 vs CON and 16.2%±6.4%, P<0.01 vs CON), respectively. CHE and GF, both PKC inhibitors, administered 5 min before RPC or IPC completely abolished the cardioprotective effect of RPC (IS/AAR: CHE+RPC 51.2%±5.0%, GF+RPC 53.6%±6.1%, P>0.05 vs CON) or IPC (CHE+IPC 53.7%±4.3%, GF+IPC 54.1%±6.2%, P>0.05 vs CON). The difference was not significant in any of the hemodynamic parameters between control and treatment groups during ischemia and reperfusion. Conclusion: Remifentanil confers myocardial protection against ischemic injury through a mechanism that is similar to IPC and involves PKC activation. ©2005 CPS and SIMM.en_HK
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/aps/index.htmlen_HK
dc.relation.ispartofActa Pharmacologica Sinicaen_HK
dc.subjectChelerythrineen_HK
dc.subjectGF109203Xen_HK
dc.subjectMyocardial ischemia preconditioningen_HK
dc.subjectMyocardial reperfusion injuryen_HK
dc.subjectProtein kinase Cen_HK
dc.subjectRemifentanilen_HK
dc.subject.meshCardiotonic Agents - pharmacology-
dc.subject.meshIschemic Preconditioning, Myocardial-
dc.subject.meshMyocardial Infarction - pathology - physiopathology-
dc.subject.meshPiperidines - pharmacology-
dc.subject.meshProtein Kinase C - antagonists and inhibitors-
dc.titleRemifentanil mimics cardioprotective effect of ischemic preconditioning via protein kinase C activation in open chest of ratsen_HK
dc.typeArticleen_HK
dc.identifier.emailIrwin, MG:mgirwin@hku.hken_HK
dc.identifier.authorityIrwin, MG=rp00390en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1745-7254.2005.00100.xen_HK
dc.identifier.pmid15842771-
dc.identifier.scopuseid_2-s2.0-18744383380en_HK
dc.identifier.hkuros109428en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-18744383380&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issue5en_HK
dc.identifier.spage546en_HK
dc.identifier.epage550en_HK
dc.identifier.isiWOS:000229103500006-
dc.publisher.placeUnited Statesen_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats